artemisinins

Summary

Summary: A group of SESQUITERPENES and their analogs that contain a peroxide group (PEROXIDES) within an oxepin ring (OXEPINS).

Top Publications

  1. pmc Artemisinin resistance in Plasmodium falciparum malaria
    Arjen M Dondorp
    Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    N Engl J Med 361:455-67. 2009
  2. pmc Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
    Aung Pyae Phyo
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 379:1960-6. 2012
  3. pmc Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
    Arjen M Dondorp
    Mahidol Oxford Tropical Medicine Research Unit MORU, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 376:1647-57. 2010
  4. pmc Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study
    Chanaki Amaratunga
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Lancet Infect Dis 12:851-8. 2012
  5. pmc A major genome region underlying artemisinin resistance in malaria
    Ian H Cheeseman
    Texas Biomedical Research Institute, San Antonio, TX 78245, USA
    Science 336:79-82. 2012
  6. pmc Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator
    Jennifer A Flegg
    WorldWide Anti malarial Resistance Network WWARN and Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK
    Malar J 10:339. 2011
  7. ncbi Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
    Arjen Dondorp
    Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    Lancet 366:717-25. 2005
  8. ncbi Production of the antimalarial drug precursor artemisinic acid in engineered yeast
    Dae Kyun Ro
    California Institute of Quantitative Biomedical Research, Lawrence Berkeley National Laboratory, University of California, Berkeley, California 94720, USA
    Nature 440:940-3. 2006
  9. ncbi Artemisinin resistance: current status and scenarios for containment
    Arjen M Dondorp
    Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok10400, Thailand
    Nat Rev Microbiol 8:272-80. 2010
  10. pmc Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries
    Kathryn A O'Connell
    Population Services International, Malaria and Child Survival Department, P O Box 43640, Nairobi, Kenya
    Malar J 10:326. 2011

Detail Information

Publications272 found, 100 shown here

  1. pmc Artemisinin resistance in Plasmodium falciparum malaria
    Arjen M Dondorp
    Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    N Engl J Med 361:455-67. 2009
    ..There are recent concerns that the efficacy of such therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance...
  2. pmc Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study
    Aung Pyae Phyo
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 379:1960-6. 2012
    ..We aimed to establish whether artemisinin resistance has spread or emerged on the Thailand-Myanmar (Burma) border...
  3. pmc Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial
    Arjen M Dondorp
    Mahidol Oxford Tropical Medicine Research Unit MORU, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 376:1647-57. 2010
    ..We compared parenteral treatment with either artesunate or quinine in African children with severe malaria...
  4. pmc Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study
    Chanaki Amaratunga
    Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Lancet Infect Dis 12:851-8. 2012
    ..We investigated contributions of both parasite genetics and host factors to the artemisinin-resistance phenotype in Pursat, western Cambodia...
  5. pmc A major genome region underlying artemisinin resistance in malaria
    Ian H Cheeseman
    Texas Biomedical Research Institute, San Antonio, TX 78245, USA
    Science 336:79-82. 2012
    ....
  6. pmc Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator
    Jennifer A Flegg
    WorldWide Anti malarial Resistance Network WWARN and Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Churchill Hospital, Old Road, Oxford, OX3 7LJ, UK
    Malar J 10:339. 2011
    ..This lag complicates the clearance estimation, introduces observer subjectivity, and may influence the accuracy and consistency of reported results...
  7. ncbi Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
    Arjen Dondorp
    Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    Lancet 366:717-25. 2005
    ..In the treatment of severe malaria, intravenous artesunate is more rapidly acting than intravenous quinine in terms of parasite clearance, is safer, and is simpler to administer, but whether it can reduce mortality is uncertain...
  8. ncbi Production of the antimalarial drug precursor artemisinic acid in engineered yeast
    Dae Kyun Ro
    California Institute of Quantitative Biomedical Research, Lawrence Berkeley National Laboratory, University of California, Berkeley, California 94720, USA
    Nature 440:940-3. 2006
    ..annua, yield optimization and industrial scale-up will be required to raise artemisinic acid production to a level high enough to reduce artemisinin combination therapies to significantly below their current prices...
  9. ncbi Artemisinin resistance: current status and scenarios for containment
    Arjen M Dondorp
    Mahidol Oxford Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok10400, Thailand
    Nat Rev Microbiol 8:272-80. 2010
    ..to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region...
  10. pmc Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries
    Kathryn A O'Connell
    Population Services International, Malaria and Child Survival Department, P O Box 43640, Nairobi, Kenya
    Malar J 10:326. 2011
    ..This paper presents supply side data from ACTwatch outlet surveys in Benin, the Democratic Republic of Congo (DRC), Madagascar, Nigeria, Uganda and Zambia...
  11. pmc Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment
    Verena Ilona Carrara
    Shoklo Malaria Research Unit, Tak, Thailand
    PLoS ONE 4:e4551. 2009
    ....
  12. pmc Monitoring fever treatment behaviour and equitable access to effective medicines in the context of initiatives to improve ACT access: baseline results and implications for programming in six African countries
    Megan Littrell
    Population Services International, Malaria and Child Survival Department, PO Box 43640, Nairobi, Kenya, Africa
    Malar J 10:327. 2011
    ..These data provide a baseline for monitoring interventions to increase ACT coverage, such as the Affordable Medicines Facility for malaria (AMFm)...
  13. pmc Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
    ....
  14. pmc Changes in health workers' malaria diagnosis and treatment practices in Kenya
    Elizabeth Juma
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, PO Box 43640, 00100 GPO, Nairobi, Kenya
    Malar J 10:1. 2011
    ..Three years after the policy implementation, health workers' adherence to malaria diagnosis and treatment recommendations was evaluated...
  15. pmc Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial
    Kojo Yeboah-Antwi
    Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000340. 2010
    ..This study was designed to assess the effectiveness and feasibility of using CHWs to manage nonsevere pneumonia and uncomplicated malaria with the aid of rapid diagnostic tests (RDTs)...
  16. ncbi Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum
    M B Reed
    The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
    Nature 403:906-9. 2000
    ..This has important implications for the development and efficacy of future antimalarial agents...
  17. ncbi Artemisinins target the SERCA of Plasmodium falciparum
    U Eckstein-Ludwig
    Department of Cellular and Molecular Medicine, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Nature 424:957-61. 2003
    b>Artemisinins are extracted from sweet wormwood (Artemisia annua) and are the most potent antimalarials available, rapidly killing all asexual stages of Plasmodium falciparum...
  18. ncbi Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia
    Harald Noedl
    Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria
    Clin Infect Dis 51:e82-9. 2010
    ..This article provides additional data from a clinical trial that has been published in The New England Journal of Medicine...
  19. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
    ..To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania...
  20. pmc Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial
    Aung Pyae Phyo
    Shoklo Malaria Research Unit, Mae Sod
    Clin Infect Dis 53:977-84. 2011
    ..Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ seems to be spreading, and alternative treatments are required...
  21. pmc Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial
    Quique Bassat
    Barcelona Centre for International Health Research CRESIB, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Universitat de Barcelona, Barcelona, Spain
    PLoS ONE 4:e7871. 2009
    ..Dihydroartemisinin-piperaquine (DHA-PQP) is a promising fixed-dose ACT with limited information on its safety and efficacy in African children...
  22. pmc The parasite clearance curve
    N J White
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Malar J 10:278. 2011
    ..The factors affecting parasite clearance are reviewed. Methods of presentation and the approaches to analysis are discussed...
  23. pmc Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial
    Frank Smithuis
    Medecins Sans Frontieres Holland, Yangon, Myanmar
    Lancet Infect Dis 10:673-81. 2010
    ..We aimed to compare effectiveness of four fixed-dose ACTs and a loose tablet combination of artesunate and mefloquine, and assess the addition of a single gametocytocidal dose of primaquine...
  24. pmc Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia
    Hailemariam Lemma
    Tigray Health Bureau, Mekelle, Ethiopia
    Malar J 10:349. 2011
    ..The aim of this study was to measure patient adherence levels to the six-dose AL regimen for the treatment of uncomplicated P. falciparum malaria and to identify its determinant factors in rural areas of the Tigray region, Ethiopia..
  25. pmc Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial
    Yi Poravuth
    National Malaria Center, Phnom Penh, Cambodia
    PLoS ONE 6:e14501. 2011
    ..New antimalarials are needed for P. vivax and P. falciparum malaria. This study compared the efficacy and safety of pyronaridine-artesunate with that of chloroquine for the treatment of uncomplicated P. vivax malaria...
  26. pmc Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia
    Shunmay Yeung
    Department of Global Health and Development, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, 15 17 Tavistock Place, London WC1H 9SH, UK
    Malar J 10:243. 2011
    ..treatment with artemisinin combination therapy (ACT) and others are already facing parasites resistant to artemisinins.In this context, there is a crucial need to improve both access to and targeting of ACT through greater ..
  27. pmc Artemisinin combination therapy for vivax malaria
    Nicholas M Douglas
    Menzies School of Health Research, Darwin, NT, Australia
    Lancet Infect Dis 10:405-16. 2010
    ..Analyses of the cost-effectiveness of ACTs for both Plasmodium species are needed to assess the role of these drugs in the control and elimination of vivax malaria...
  28. ncbi In vivo parasitological measures of artemisinin susceptibility
    Kasia Stepniewska
    Mahidol Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
    J Infect Dis 201:570-9. 2010
    ....
  29. ncbi Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial
    Jacek Skarbinski
    Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3724, USA
    Am J Trop Med Hyg 80:919-26. 2009
    ..30). RDTs could potentially improve malaria case management, but we urgently need to develop more effective strategies for implementing guidelines before large scale implementation...
  30. pmc Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria
    J Tarning
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Clin Pharmacol Ther 91:497-505. 2012
    ..025) but had significantly lower day 7 piperaquine concentrations (P = 0.024) and total piperaquine exposures (P = 0.021), suggesting that an increased dose regimen for young children should be evaluated...
  31. pmc Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs
    Teun Bousema
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    Malar J 9:136. 2010
    ..Simple mathematical models were fitted to data from clinical trials in order to determine the mean gametocyte circulation time and duration of gametocyte carriage in treated malaria patients...
  32. ncbi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
    Emmanuel Arinaitwe
    Makerere University University of California San Francisco Research Collaboration, University of California, San Francisco 94143, USA
    Clin Infect Dis 49:1629-37. 2009
    ..However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children...
  33. pmc In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009
    ..Identification of drug-specific parasite determinants that contribute to treatment failures will provide important tools for the detection and surveillance of AL resistance...
  34. pmc Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance
    Maria Isabel Veiga
    Malaria Research Lab, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    PLoS ONE 6:e20212. 2011
    ..Southeast Asia is an epicenter of emerging antimalarial drug resistance, including recent resistance to the artemisinins, the core component of all recommended antimalarial combination therapies...
  35. pmc Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
    Michael Nambozi
    Department of Clinical Sciences, Tropical Disease Research Center, P, O Box 71769, Ndola Zambia
    Malar J 10:50. 2011
    ..In 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (AL) that has proved to be highly efficacious against multidrug resistant Plasmodium falciparum...
  36. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
    ..This points to 86N as a potential marker of lumefantrine resistance in vivo, while suggesting that Coartem is not robust enough to avoid selection of resistance-associated mutations in some malarial settings...
  37. pmc Poor quality vital anti-malarials in Africa - an urgent neglected public health priority
    Paul N Newton
    Wellcome Trust Mahosot Hospital Oxford University Tropical Medicine Research Collaboration, Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR
    Malar J 10:352. 2011
    ..A vital component of malaria control rests on the availability of good quality artemisinin-derivative based combination therapy (ACT) at the correct dose. However, there are increasing reports of poor quality anti-malarials in Africa...
  38. pmc Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin
    Amar bir Singh Sidhu
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, Bronx, NY 10461, USA
    J Infect Dis 194:528-35. 2006
    ..These results highlight the importance of pfmdr1 copy number in determining P. falciparum susceptibility to multiple agents currently being used to combat malaria caused by multidrug-resistant parasites...
  39. pmc Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya
    Andrew Nyandigisi
    Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
    PLoS ONE 6:e24781. 2011
    ..We evaluated changes in health systems and case-management indicators between the baseline survey undertaken before implementation of the policy and the follow-up survey following the first year of the implementation activities...
  40. pmc In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1
    Leah Mwai
    Kenya Medical Research Institute KEMRI Wellcome Trust Collaborative Research Program, Kilifi, Kenya
    Antimicrob Agents Chemother 53:5069-73. 2009
    ..Therefore, the use of LM-artemether is likely to lead to the selection of more CQ-susceptible parasites...
  41. pmc Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009
    ..The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector...
  42. pmc Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations
    Amar bir Singh Sidhu
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Science 298:210-3. 2002
    ..pfcrt mutations increased susceptibility to artemisinin and quinine and minimally affected amodiaquine activity; hence, these antimalarials warrant further investigation as agents to control chloroquine-resistant falciparum malaria...
  43. pmc Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia
    Pharath Lim
    Institut Pasteur in Cambodia, Phnom Penh, Cambodia
    Malar J 8:11. 2009
    ....
  44. pmc Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
    Steffen Borrmann
    Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya
    PLoS ONE 6:e26005. 2011
    ..The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies...
  45. ncbi Adherence to artemether/lumefantrine treatment in children under real-life situations in rural Tanzania
    Daudi O Simba
    Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
    Trans R Soc Trop Med Hyg 106:3-9. 2012
    ....
  46. pmc No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali
    Amelia W Maiga
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy, and Odonto Stomatology, University of Bamako, Mali
    Am J Trop Med Hyg 87:23-8. 2012
    Plasmodium falciparum resistance to artemisinins by delayed parasite clearance is present in Southeast Asia...
  47. pmc SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology
    Jim Barrington
    SMS for Life Program Director, Forum 1 P 94, Novartis Campus, CH 4056 Basel, Switzerland
    Malar J 9:298. 2010
    ..Lack of visibility of anti-malarial stock levels at the health facility level is an important contributor to this problem...
  48. ncbi Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi
    Kimberly E Mace
    Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 53:772-9. 2011
    ..Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation...
  49. ncbi Efficacy and safety of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomised controlled studies
    Cho Naing
    School of Postgraduate Studies and Research, International Medical University, Kuala Lumpur 57000, Malaysia
    Trans R Soc Trop Med Hyg 107:65-73. 2013
    ..The better safety profile of DP and once-daily dosage improves adherence and its fixed co-formulation ensures that both drugs are taken together. Our conclusion is that DP has the potential to become a first-line antimalarial drug...
  50. pmc The ACTwatch project: methods to describe anti-malarial markets in seven countries
    Tanya Shewchuk
    Malaria and Child Survival Department, Population Services International, P, O, Box 43640 00800, Nairobi, Kenya, Africa
    Malar J 10:325. 2011
    ..The project is designed to provide a comprehensive picture of the anti-malarial market to inform national and international anti-malarial drug policy decision-making...
  51. pmc The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya
    Raymond K Sudoi
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, PO Box 43640, 00100 GPO Nairobi, Kenya
    Malar J 11:37. 2012
    ..Here, 2010-2011 data are reported from public facilities in Kenya where alarming stock-outs were revealed in 2008...
  52. pmc Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial
    Jean Louis A Ndiaye
    Department of Medical Parasitology, Medical Faculty, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 10:237. 2011
    ....
  53. pmc Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion
    Nectarios Klonis
    Department of Biochemistry and Australian Research Council Centre of Excellence for Coherent X ray Science, La Trobe University, 3086 Melbourne, Australia
    Proc Natl Acad Sci U S A 108:11405-10. 2011
    ..We treated Plasmodium falciparum for periods of a few hours to mimic clinical exposure to the short half-life artemisinins. We found that drug treatment retards parasite growth and inhibits uptake of hemoglobin, even at sublethal ..
  54. pmc The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
    Beth P Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Research Programme, Kenya
    PLoS Med 8:e1000437. 2011
    ..This study in western Kenya aimed to evaluate the impact of providing subsidized artemether-lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3-59 months...
  55. ncbi The genetic map of Artemisia annua L. identifies loci affecting yield of the antimalarial drug artemisinin
    Ian A Graham
    Centre for Novel Agricultural Products, Department of Biology, University of York, York YO10 5YW, UK
    Science 327:328-31. 2010
    ..Enrichment for positive QTLs in parents of new high-yielding hybrids confirms that the knowledge and tools to convert A. annua into a robust crop are now available...
  56. pmc Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure
    Franka Teuscher
    Malaria Drug Resistance and Chemotherapy Laboratory, Queensland Institute of Medical Research, Australian Army Malaria Institute, Brisbane, Australia
    J Infect Dis 202:1362-8. 2010
    ..The temporary arrest of the growth of ring-stage parasites (dormancy) after exposure to artemisinin drugs provides a plausible explanation for this phenomenon...
  57. pmc The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia
    Richard J Maude
    Faculty of Tropical Medicine, Mahidol University, Rajthevee, Bangkok 10400, Thailand
    Malar J 8:31. 2009
    ..The use of such an approach to investigate the likely effectiveness of different containment measures with the ultimate aim of eliminating artemisinin-resistant malaria is described...
  58. ncbi Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum
    J Teun Bousema
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Infect Dis 193:1151-9. 2006
    ....
  59. pmc Decreased in vitro susceptibility of Plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007
    Pharath Lim
    Institut Pasteur in Cambodia, Molecular Epidemiology Unit, Phnom Penh, Cambodia
    Antimicrob Agents Chemother 54:2135-42. 2010
    ..These results are worrisome, because they may signal deterioration of the efficacy of artesunate-mefloquine beyond the Cambodian-Thai border...
  60. pmc Intrahost modeling of artemisinin resistance in Plasmodium falciparum
    Sompob Saralamba
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Rajthevee, Bangkok 10400, Thailand
    Proc Natl Acad Sci U S A 108:397-402. 2011
    ..This result supports the hypothesis that artemisinin resistance mainly reflects reduced ring-stage susceptibility and predicts that doubling the frequency of dosing will accelerate clearance of artemisinin-resistant parasites...
  61. pmc Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria
    Joel Tarning
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Antimicrob Agents Chemother 53:3837-46. 2009
    ..In conclusion, altered pharmacokinetic properties of lumefantrine contribute to the high rates of failure of artemether-lumefantrine treatment in later pregnancy. Dose optimization is urgently needed...
  62. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
    ..Artemisinin-based combination therapy has made a substantial contribution to reducing the burden of malaria in sub-Saharan Africa...
  63. ncbi Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6)
    Sabina Dahlström
    Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Infect Genet Evol 8:340-5. 2008
    ..Plasmodium falciparum (PfATP6) has been suggested to be involved in the mechanism of action and resistance to artemisinins, the main constituent of artemisinin-based combination therapy (ACT)...
  64. pmc High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia
    Tim J C Anderson
    Southwest Foundation for Biomedical Research, PO Box 760549, San Antonio, Texas 78245, USA
    J Infect Dis 201:1326-30. 2010
    ....
  65. pmc Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance
    Nicholas J White
    Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, 420 6 Rajvithi Road, Bangkok 10400, Thailand
    Malar J 8:253. 2009
    ..The importance of anti-malarial treatment dosing has been underappreciated. Treatment recommendations are often for the lowest doses that produce "satisfactory" results...
  66. pmc Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatment
    Mac Otten
    World Health Organization, Global Malaria Program, Geneva, Switzerland
    Malar J 8:14. 2009
    ....
  67. pmc Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial
    Lorenz von Seidlein
    Department of Global Health, Menzies School of Health Research, Casuarina, Northern Territory, Australia
    Clin Infect Dis 54:1080-90. 2012
    ..Data from the largest randomized, controlled trial for the treatment of children hospitalized with severe malaria were used to identify such predictors of a poor outcome from severe malaria...
  68. ncbi The molecular mechanism of action of artemisinin--the debate continues
    Paul M O'Neill
    Department of Chemistry, University of Liverpool, Oxford Street, Liverpool L697ZD, UK
    Molecules 15:1705-21. 2010
    ..After a major change in treatment policies, artemisinins are now the frontline treatment to aid rapid clearance of parasitaemia and quick resolution of symptoms...
  69. pmc Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
    Julien Zwang
    Shoklo Malaria Research Unit, Mae Sot, Thailand
    Malar J 8:203. 2009
    ..It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an evidence-based drug policy...
  70. ncbi Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial
    Antoinette K Tshefu
    Ecole de Santé Publique, Faculte de Medecine, Universite de Kinshasa, Kinshasa, Democratic Republic of the Congo
    Lancet 375:1457-67. 2010
    ..We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P falciparum malaria...
  71. pmc Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space
    Naman K Shah
    Department of Epidemiology, University of North Carolina, Chapel Hill, USA
    Lancet Infect Dis 11:57-64. 2011
    ..Strategies to reduce the emergence and spread of future drug resistance need to be proactive and supported by intensive monitoring...
  72. pmc Declining in efficacy of a three-day combination regimen of mefloquine-artesunate in a multi-drug resistance area along the Thai-Myanmar border
    Kesara Na-Bangchang
    Graduate Programme in Biomedical Sciences, Thammasat University, Thailand
    Malar J 9:273. 2010
    ....
  73. pmc Feasibility and acceptability of home-based management of malaria strategy adapted to Sudan's conditions using artemisinin-based combination therapy and rapid diagnostic test
    Khalid A Elmardi
    National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan
    Malar J 8:39. 2009
    ..This research aimed to assess the feasibility and acceptability of home-based management of malaria (HMM) strategy using artemisinin-based combination therapy (ACT) for treatment and rapid diagnostic test (RDT) for diagnosis...
  74. pmc Quality of malaria case management at outpatient health facilities in Angola
    Alexander K Rowe
    Centers for Disease Control and Prevention, Atlanta, USA
    Malar J 8:275. 2009
    ..Implementation was complicated by a policy that was sometimes ambiguous...
  75. pmc Intravenous artesunate for severe malaria in travelers, Europe
    Thomas Zoller
    Charite Universitatsmedizin, Berlin, Germany
    Emerg Infect Dis 17:771-7. 2011
    ..IV artesunate was an effective alternative to quinine for treatment of malaria patients in Europe. Patients should be monitored for signs of hemolysis, especially after parasitologic cure...
  76. pmc Malaria case-management under artemether-lumefantrine treatment policy in Uganda
    Dejan Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Malar J 7:181. 2008
    ..Here the quality of AL case-management is reported from Uganda; approximately one year after AL replaced combination of chloroquine and sulphadoxine-pyrimethamine (CQ+SP) as recommended first line treatment for uncomplicated malaria...
  77. pmc Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial
    Jane Achan
    Makerere University School of Health Sciences, PO Box 7475, Kampala, Uganda
    BMJ 339:b2763. 2009
    ..To compare the effectiveness of oral quinine with that of artemether-lumefantrine in treating uncomplicated malaria in children...
  78. pmc Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial
    Delia Bethell
    Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
    PLoS ONE 6:e19283. 2011
    ..This study investigated the impact of different AS doses on clinical and parasitological responses in malaria patients from an area of known artemisinin resistance in western Cambodia...
  79. pmc Progress towards implementation of ACT malaria case-management in public health facilities in the Republic of Sudan: a cluster-sample survey
    Tarig M Abdelgader
    Malaria Public Health and Epidemiology Group, Centre for Geographic Medicine Research Coast, Kenya Medical Research Institute Wellcome Trust Research Programme, Nairobi, Kenya
    BMC Public Health 12:11. 2012
    ..Three years after the launch of the strategy a health facility survey was undertaken to evaluate case-management practices and readiness of the health facilities and health workers to implement a new malaria case-management strategy...
  80. ncbi Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite
    A V Pandey
    Malaria Research Group, International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, P O Box 10504, New Delhi 110 067, India
    J Biol Chem 274:19383-8. 1999
    ....
  81. pmc Early parasitological response following artemisinin-containing regimens: a critical review of the literature
    Debashish Das
    WorldWide Antimalarial Resistance Network, Oxford, UK
    Malar J 12:125. 2013
    ..Parasitaemia on Day 3 has been proposed as a useful alert of potential artemisinin resistance, however, the normal variation of parasite clearance observed in artemisinin-based combination therapy clinical trials is poorly documented...
  82. ncbi Artemisinins and the biological basis for the PfATP6/SERCA hypothesis
    Sanjeev Krishna
    Centre for Infection, Cellular and Molecular Medicine, St George s University of London, Cranmer Terrace, London, UK, SW17 0RE
    Trends Parasitol 26:517-23. 2010
    ..Herein, evidence is discussed that relates to this hypothesis as alternative suggestions for how artemisinins might act have been reviewed elsewhere.
  83. ncbi Pyronaridine-artesunate versus mefloquine plus artesunate for malaria
    Ronnatrai Rueangweerayut
    Department of Internal Medicine, Mae Sot General Hospital, Tak, Thailand
    N Engl J Med 366:1298-309. 2012
    ..Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria...
  84. ncbi Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets
    Xavier C Ding
    Centre suisse de recherches scientifiques en Côte d Ivoire, 01 BP 1303, Abidjan 01, Cote d Ivoire
    Trends Parasitol 27:73-81. 2011
    b>Artemisinins are efficacious antimalarial drugs widely employed as first-line treatment in endemic countries under the form of combined therapies...
  85. pmc Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine
    Nahla B Gadalla
    Department of Epidemiology, Tropical Medicine Research Institute, National Centre for Research, Khartoum, Sudan
    Antimicrob Agents Chemother 55:5408-11. 2011
    ..One individual carried parasites with a novel pfmdr1 polymorphism (F1044L). pfmdr1 gene amplification in parasites prior to treatment occurred in three individuals who had recurrent infection during follow-up...
  86. pmc Treatment of imported severe malaria with artesunate instead of quinine--more evidence needed?
    Jakob P Cramer
    Bernhard Nocht Clinic for Tropical Medicine, I, Department of Tropical Medicine, University Medical Center Hamburg Eppendorf, Bernhard Nocht Strasse 74, 20359 Hamburg, Germany
    Malar J 10:256. 2011
    ..Here, the implications of existing evidence for the treatment of imported severe malaria are discussed...
  87. ncbi Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
    Ric N Price
    Department of Cellular and Molecular Medicine Infectious Diseases, St George s Hospital Medical School, London, UK
    Lancet 364:438-47. 2004
    ..A combination of artesunate with mefloquine now cures more than 95% of acute infections. For both treatment regimens, the underlying mechanisms of resistance are not known...
  88. pmc Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective
    Sandra Alba
    Dept Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Malar J 9:164. 2010
    ..Subsidized ALu was made available in both health facilities and ADDOs. The effect of these interventions on access to malaria treatment was studied in rural Tanzania...
  89. ncbi Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda
    Carole Fogg
    Epicentre, Paris, France
    Am J Trop Med Hyg 71:525-30. 2004
    ..The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations...
  90. pmc Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium
    Annemarie R Kreeftmeijer-Vegter
    Department of Internal Medicine, Division of Infectious Diseases, Academic Medical Center, Amsterdam, The Netherlands
    Malar J 11:102. 2012
    ..Fortunately, artesunate became available in the Netherlands and Belgium through a named patient programme. This is the largest case series of artesunate treated patients with severe malaria in Europe...
  91. ncbi Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
    Patrice Piola
    Epicentre, Paris, France
    Lancet Infect Dis 10:762-9. 2010
    ..We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda...
  92. ncbi A trial of combination antimalarial therapies in children from Papua New Guinea
    Harin A Karunajeewa
    School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
    N Engl J Med 359:2545-57. 2008
    ..Malaria control is difficult where there is intense year-round transmission of multiple plasmodium species, such as in Papua New Guinea...
  93. pmc Pharmacokinetics and pharmacodynamics of artesunate and dihydroartemisinin following oral treatment in pregnant women with asymptomatic Plasmodium falciparum infections in Kinshasa DRC
    Marie A Onyamboko
    Kinshasa School of Public Health, Kinshasa, the Democratic Republic of Congo
    Malar J 10:49. 2011
    ..Artemisinin-based IPT regimens represent a promising potential alternative to SP. Pharmacokinetic and safety data supporting the use of artemisinin derivatives in pregnancy are urgently needed...
  94. pmc A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children
    Babacar Faye
    Department of Parasitology, Faculty of Medicine, University Cheikh Anta Diop, Dakar, Senegal
    Am J Trop Med Hyg 82:140-4. 2010
    ..No biological significant abnormal values related to the study drug have been reported. The new pediatric artesunate mefloquine formulated in granule fixed dose combination is well adapted to children in Africa...
  95. pmc Health worker performance in the management of paediatric fevers following in-service training and exposure to job aids in Kenya
    Beatrice Wasunna
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast CGMRC, Nairobi, Kenya Nairobi, Kenya
    Malar J 9:261. 2010
    ..In 2007, a new initiative was launched in one part of Kenya to improve malaria case-management through enhanced in-service training and provision of job aids...
  96. pmc Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation study
    Mwinyi I Msellem
    Malaria Control Programme, Ministry of Health and Social Welfare, Zanzibar, Tanzania
    PLoS Med 6:e1000070. 2009
    ..Our objective was to study the influence of RDT-aided malaria diagnosis on drug prescriptions, health outcomes, and costs in primary health care settings...
  97. pmc Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo
    Ji Hui Du
    Central Laboratory, Nanshan Hospital, Guangdong Medical College, 518052 Shenzhen, Guangdong Province, People s Republic of China
    Cancer Chemother Pharmacol 65:895-902. 2010
    ....
  98. pmc A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya
    Petra F Mens
    Koninklijk Instituut voor de Tropen KIT Royal Tropical Institute, KIT Biomedical Research, Amsterdam, The Netherlands
    Malar J 7:237. 2008
    ....
  99. pmc Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia
    William O Rogers
    Naval Medical Research Unit 2, Komp, P2P PLP LITBANGKES, Jl, Percetakan Negara No, 29, Jakarta 10560, Indonesia
    Malar J 8:10. 2009
    ..The efficacy of standard therapies for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria was assessed in Chumkiri, Kampot Province, Cambodia...
  100. pmc Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children
    Badara Cisse
    Department of Parasitology and Mycology, Universite Cheikh Anta Diop, Dakar, Senegal
    PLoS ONE 4:e7164. 2009
    ....
  101. pmc Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial
    Margaret Kweku
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 3:e4000. 2008
    ....

Research Grants51

  1. FOSMIDOMYCIN RESISTANCE IN PLASMODIUM FALCIPARUM
    AUDREY RAGAN ODOM; Fiscal Year: 2013
    ..are urgently needed to treat this disease, due to widespread chloroquine resistance and emerging resistance to artemisinins. P...
  2. Novel Artemisinin Derivatives for Cytomegalovirus Therapy
    RAVIT BOGER; Fiscal Year: 2013
    ..The overall goal of this application is to investigate the anti-CMV activities of artemisinins. Several artemisinin derivatives are widely used in malaria therapy...
  3. Role of pfcrt in chloroquine resistance in P. falciparum
    DAVID ARMAND FIDOCK; Fiscal Year: 2013
    ..of this former gold-standard antimalarial, and in SE Asia we are now witnessing the emergence of resistance to artemisinins, the fast-acting but very rapidly cleared core component of artemisinin-based combination therapies (ACTs)...
  4. Testing feasibility of artemisinin-based synthetic-lethal suppression of skin pho
    Georg T Wondrak; Fiscal Year: 2013
    ..Our recent research has identified artemisinins, an important class of redox-anti-malarials in clinical use worldwide, as synthetic- lethal anticancer agents ..
  5. Southeast Asia Malaria Research Center
    Liwang Cui; Fiscal Year: 2013
    ..Emerging resistance of parasites to artemisinins and circulation of counterfeit/substandard artemisinin drugs that threaten regional and global malaria control ..
  6. Within Host Selection of P. falciparum Variants by Artemisinin Combination Therap
    JONATHAN JAMES JULIANO; Fiscal Year: 2013
    ..to define selection coefficients and better define the phenotype used to study drug resistance to artemisinins. This novel approach of quantitatively studying variant diversity within individuals will i) allow accurate ..
  7. Population biology of malaria drug resistance in Yunnan
    Zhaoqing Yang; Fiscal Year: 2010
    ..To choose the best partner drug for artemisinins for a specific region, it is essential to have a comprehensive knowledge of drug resistance in the parasite ..
  8. Mechanisms of anti-schistosome artemisinin chemotherapy
    David Williams; Fiscal Year: 2006
    ..b>Artemisinins are a new class of antimalarial and antischistosomal compounds that are thought to function via artemisinin ..
  9. Economical production of artemisinin precursors
    Jack Newman; Fiscal Year: 2004
    ..b>Artemisinins, terpenoid compounds derived from traditional Chinese medicines used for centuries, have been acclaimed as the ..
  10. Economical production of artemisinin precursors
    Jack Newman; Fiscal Year: 2005
    ..b>Artemisinins, terpenoid compounds derived from traditional Chinese medicines used for centuries, have been acclaimed as the ..
  11. TRIOXANES FOR CHEMOTHERAPY OF MALARIA AND CANCER
    Gary Posner; Fiscal Year: 2005
    ....
  12. Chemoprevention/Therapy Using Non-Calcemic Vitamin D
    Gary Posner; Fiscal Year: 2006
    ..Collectively, these studies will provide important structure- activity insights into the cancer chemoprotective and chemotherapeutic actions and molecular biology of vitamin D3 analogs. ..
  13. New Topical Therapies for Psoriasis
    Mitchell Avery; Fiscal Year: 2007
    ..The goal of this project is to develop a safe and effective new drug for topical treatment of psoriasis. [unreadable] [unreadable] [unreadable]..
  14. DEVELOPMENT OF NOVEL ANTIFUNGAL ANTIPC NATURAL PRODUCTS
    Mitchell Avery; Fiscal Year: 2001
    ....
  15. Dev & Testing of New Medications for Treatment of Emerging Infectious Diseases
    Mitchell Avery; Fiscal Year: 2006
    ..This allows LADDS infrastructure to inch forward now to the last stages of drug development that are achievable with academic economics. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  16. Burden of Malaria in Pregnancy in India
    Davidson Hamer; Fiscal Year: 2007
    ..The information generated by the study will also be instrumental in the development of new programs for preventing and mitigating the impact of MIP in India. [unreadable] [unreadable] [unreadable]..
  17. Congenital and neonatal malaria in Mali
    Abdoulaye Djimde; Fiscal Year: 2006
    ..research grant ..
  18. Development of a cell-based method for high-throughput drug screening in malaria
    Liwang Cui; Fiscal Year: 2008
    ..To facilitate antimalarial drug discovery, we propose to develop a highly sensitive, cell-based, one-step luminescent drug screen assay for high throughput screening of large chemical libraries. [unreadable] [unreadable] [unreadable]..
  19. Translational Control in Plasmodium Sexual Development
    Liwang Cui; Fiscal Year: 2005
    ....
  20. Pathogenesis of falciparum malaria in infancy
    Patrick Duffy; Fiscal Year: 2004
    ..Identifying new therapies for children is an urgent public health goal, but is not a funding priority for the United States Department of Defense. ..
  21. A randomized, controlled clinical trial of chloroquine as chemoprophylaxis versus
    MIRIAM LAUFER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  22. Molecular epidemiology of drug resistant malaria
    MIRIAM LAUFER; Fiscal Year: 2008
    ..abstract_text> ..
  23. Biosensors for metabolic engineering
    Jay Keasling; Fiscal Year: 2006
    ..abstract_text> ..
  24. Plasmodium vivax:Proteomic Analysis of Asexual and Sporozoite Stages
    Liwang Cui; Fiscal Year: 2007
    ..Its recent resurgence in prevalence and emergence of drug- resistant parasite strains have raised a great concern for the future control of malaria. [unreadable] [unreadable] [unreadable]..
  25. MAPPING DRUG RESISTANCE GENES IN PLASMODIUM FALCIPARUM
    Tim J Anderson; Fiscal Year: 2010
    ..We aim to locate parasite genes underlying resistance. This will allow us to track the spread of resistance, to better understand how antimalarial drugs work, and to redesign drugs to restore their effectiveness. ..
  26. A Linkage Map for Schistosoma mansoni
    Tim Anderson; Fiscal Year: 2008
    ..Development of a linkage map will pave the way for finding these genes. [unreadable] [unreadable] [unreadable]..
  27. MATERNAL MALARIA--PARASITE ADHESION AND ANTIBODIES
    Patrick Duffy; Fiscal Year: 2001
    ..Further, the delineation of binding domains and B cell epitopes will provide the basis to design an anti-adhesion vaccine to protect primigravid and other women susceptible to placental infection with the CSA-binding parasites. ..
  28. Pittsburgh Molecular Libraries Screening Center(RMI)
    JOHN LAZO; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  29. DRUGS AND DELIVERY SYSTEMS FOR OPPORTUNISTIC INFECTIONS
    Marvin Miller; Fiscal Year: 2002
    ....
  30. Plasmodium Falciparum Metal Metabolism
    David Sullivan; Fiscal Year: 2009
    Interference with Plasmodium metal metabolism by the quinolines and artemisinins is a proven chemotherapeutic target...
  31. YEAST MODELS OF DRUG-RESISTANT PNEUMOCYSTIS CARINII
    Steven Meshnick; Fiscal Year: 2004
    ..Ultimately, it is hoped that the results of this study will facilitate the rational use of antipneumocystis drugs. ..
  32. TOTAL SYNTHESIS OF SCABRONINE A
    GREGORY DUDLEY; Fiscal Year: 2002
    ..The proposed strategy utilizes a novel coupling annulation to assemble the seven-membered ring. ..
  33. BIOCHEMICAL REGULATORS OF BLEOMYCIN INDUCED TUMORS
    JOHN LAZO; Fiscal Year: 2001
    ..The Specific Aims are to: 1) develop cells and mice deficient in BH, 2) develop cells and mice that overexpress BH, 3) isolate and characterize potential proteins that interact with BH and, 4) analyze the regulation of BH expression. ..
  34. Plainning malaria training in Zambia
    Thomas Eisele; Fiscal Year: 2009
    ..Tailoring a sustainable program using appropriate technology and a framework of collaboration in support of PMI activities will greatly increase the likelihood of controlling, and perhaps eventually eliminating, malaria in Zambia. ..
  35. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis
    Mahmoud Elsohly; Fiscal Year: 2006
    ..This proposal addresses a major public health problem, namely contact allergic dermatitis and promises the development of an effective agent to address this problem. [unreadable] [unreadable]..
  36. MALARIA AND HIV IN PREGNANT WOMEN IN MALAWI
    Steven Meshnick; Fiscal Year: 2005
    ..The results of this study will have important implications for designing public health program s for antenatal care in African and should promote our understanding of the pathogenesis of MTCT. ..
  37. Bioactive Compounds from Acylnitroso Cycloadducts
    Marvin Miller; Fiscal Year: 2006
    ..abstract_text> ..
  38. In Vitro High Throughput Screening Assay for MKP-1(RMI)
    JOHN LAZO; Fiscal Year: 2005
    ..No potent or selective small molecule inhibitors of this protein phosphatase are known. This proposal will provide sufficient reagents to permit a high throughput screening of 100,000 compounds. ..
  39. In Vitro High Throughput Screening Assay for MKP-3(RMI)
    JOHN LAZO; Fiscal Year: 2005
    ..Nonetheless, no potent or selective small molecule inhibitors of this protein phosphatase have been identified. This proposal will provide sufficient reagents to permit a high throughput screening of 100,000 compounds ..
  40. Transmucosal Intra-Oral Drug Delivery System for THC
    Mahmoud Elsohly; Fiscal Year: 2003
    ..abstract_text> ..
  41. Derivatization/Functionalization of Natural Product(RMI)
    Marvin Miller; Fiscal Year: 2007
    ..3. Broadly test the scaffold and derived libraries of novel compounds using the extensive set of assays in place at the Hans-Knoll Institute for Natural Products Research (HKI). ..
  42. Bleomycin Hydrolase and Alzheimer's Disease
    JOHN LAZO; Fiscal Year: 2004
    ..These studies should provide new mechanistic information concerning the pathogenesis of AD as well as reagents for future therapeutic studies. ..
  43. Chemical Complementation Assay for MKP-3 (RMI)
    JOHN LAZO; Fiscal Year: 2005
    ..This proposal will provide sufficient reagents, including cells and DMA transfection vectors, to permit the high throughput screening of 100,000 compounds. ..
  44. Molecular Epidemiology of Primary CMV Infection
    RAVIT BOGER; Fiscal Year: 2008
    ..This application will improve our understanding of acute CMV infection and will open new research directions in vaccine development. . [unreadable] [unreadable] [unreadable] [unreadable]..
  45. Routes of Transmission of HIV in Malawian Mothers
    Steven Meshnick; Fiscal Year: 2006
    ..Thus, the results of this project will suggest a comprehensive model of the vector, the route, and the maternal factors associated with HIV vertical transmission. ..
  46. Chemical Complementation Assay for MKP-1 (RMI)
    JOHN LAZO; Fiscal Year: 2005
    ..This proposal will provide sufficient reagents, including cells and DMA transfection vectors, to permit the high throughput screening of 100,000 compounds. ..
  47. IMMUNE RESPONSES TO P FALCIPARUM IN HIGHLAND KENYA
    Chandy John; Fiscal Year: 2002
    ..falciparum antigens to susceptibility to infection and disease is important in the evaluation of these antigens as malaria vaccine candidates. ..
  48. Transcriptional & cell cycle control by dietary indoles
    GARY FIRESTONE; Fiscal Year: 2008
    ..This information will be particularly valuable to develop new classes of I3C-based therapeutics for reproductive cancers. ..
  49. STEROID CONTROL OF EPITHELIAL CELL-CELL INTERACTIONS
    GARY FIRESTONE; Fiscal Year: 2007
    ..abstract_text> ..
  50. Host Polymorphisms and Uncomplicated Malaria
    Sunil Parikh; Fiscal Year: 2008
    ..Parikh will be able to utilize modern molecular epidemiology techniques to investigate human genetic factors underlying susceptibility to malaria and he will be well equipped for a career in academic research. ..